Abstract
Ramucirumab, a human IgG 1 antibody against vascular endothelial growth factor receptor 2, has been shown to improve progression-free survival and overall survival in patients with advanced gastric cancer in the second-line setting. To compare progression-free survival for S-1 and oxaliplatin plus ramucirumab with that for S-1 and oxaliplatin plus placebo in patients with advanced gastric cancer. This phase 2, double-blind randomized clinical trial (RAINSTORM [First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab in Patients With Advanced Gastric Cancer]) was conducted from October 12, 2015, to April 11, 2018, at 36 sites in Japan, South Korea, and Taiwan. Participants were chemotherapy-naive patients (n = 189) with metastatic gastric or gastroesophageal adenocarcinoma. Analyses of the full analysis set and safety population were conducted between November 27, 2017, and June 4, 2018. Patients randomized to the ramucirumab plus S-1 and oxaliplatin arm received S-1, 80 to 120 mg/d twice daily, on days 1 to 14 and oxaliplatin, 100 mg/m2, on day 1 with ramucirumab, 8 mg/kg, on days 1 and 8 in part A (21-day cycle). Patients randomized to the placebo plus S-1 and oxaliplatin arm received...Continue Reading
References
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Atsushi OhtsuYoon-Koo Kang
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Feb 8, 2013·Angiogenesis·Guido BocciRomano Danesi
Oct 8, 2013·Lancet·Charles S FuchsUNKNOWN REGARD Trial Investigators
Oct 22, 2013·JAMA : the Journal of the American Medical Association·UNKNOWN World Medical Association
Feb 22, 2014·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Lin ShenYongzhe Piao
Sep 23, 2014·The Lancet Oncology·Hansjochen WilkeUNKNOWN RAINBOW Study Group
Oct 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Dec 3, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtDennis Slamon
Jun 28, 2016·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·UNKNOWN Japanese Gastric Cancer Association
Oct 5, 2016·Journal of the National Comprehensive Cancer Network : JNCCN·Jaffer A AjaniHema Sundar
Oct 22, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H H YoonZ A Wainberg
Jul 2, 2017·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Kohei ShitaraKei Muro
Jul 19, 2017·Molecular Cancer Therapeutics·Josep TaberneroCharles S Fuchs
Feb 6, 2019·The Lancet Oncology·Charles S FuchsUNKNOWN RAINFALL Study Group
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Citations
Oct 2, 2019·The Oncologist·Ryan H MoyYelena Y Janjigian
Aug 1, 2020·PloS One·Almudena Cotes SanchísAlberto Carmona-Bayonas
Aug 18, 2020·Cancer Management and Research·Xin ZhangQingping Cai
May 29, 2020·Technology in Cancer Research & Treatment·Boning XiaChang Liu
May 2, 2020·Cancers·Hiroyuki Arai, Takako Eguchi Nakajima
Oct 21, 2020·Cancers·Ian ChauCharles S Fuchs
Nov 26, 2020·Cancer Discovery·Daniel V T CatenacciHedy L Kindler
Dec 19, 2020·Cancers·Anna KoumarianouMichalis V Karamouzis
Dec 18, 2020·Global Health & Medicine·Yasuhide Yamada
Mar 9, 2021·Gastroenterology Research and Practice·Hongqiong YangJunbo He
Mar 26, 2021·Advanced Healthcare Materials·Özlem ŞenGianni Ciofani
Jun 18, 2021·Indian Journal of Pathology & Microbiology·Satyajit Pawar, Atul Sharma
Jul 31, 2021·World Journal of Gastroenterology : WJG·Min ZhongJun Deng